SAUDI ARABIA Trends and Developments Contributed by: Dr Saud Alromi, Mostafa Ihab, Mohamed Ramadan and Saleh Albadry, Mohammed Al Dhabaan & Partners Eversheds Sutherland
The SFDA The SFDA monitors and controls imports and distribution of medical devices, pharmaceuti - cals, and food products. The Cooperative Council of Health Insurance (CCHI) The CCHI regulates Saudi Arabia’s health insur - ance sector. It ensures that health insurance providers comply with regulatory standards and provides oversight to protect the interests of insured individuals. Its role is particularly impor - tant as Saudi Arabia moves towards a more pri - vatised healthcare system, with increased reli - ance on private health insurance. The National Centre for Privatisation (NCP) The NCP enables the privatisation of certain government assets and services. It works to create a conducive environment for private sec - tor participation, facilitating PPPs and ensuring that privatisation initiatives align with the goals of Vision 2030. The SAIP The SAIP regulates, enhances, and protects the Kingdom’s IP landscape. The Health Holding Company (HHC) The HHC manages day-to-day administration of health services from the MoH and provides ser - vices through primary healthcare development programmes, including digital health and virtual medical care. This approach aims to improve the efficiency and quality of healthcare services in Saudi Arabia. Impact of Privatisation on Life Sciences & Pharma IP Litigation Vision 2030 aims to transform the healthcare sector through privatisation and increased pri - vate sector participation. The government plans
to invest billions of dollars to develop healthcare infrastructure, reorganise and privatise health services and insurance, and expand e-health services. This transformation is expected to cre - ate significant commercial opportunities for both local and international companies. Privatisation initiatives include the introduction of PPPs in various healthcare areas, such as pri - mary care, hospitals, medical cities, laboratories, radiology, pharmacies, rehabilitation, long-term care, and home care. The privatisation of the healthcare sector and the introduction of PPPs have created new oppor - tunities and challenges for IP litigation. Com - panies involved in PPP projects must navigate complex regulatory and IP landscapes to protect their interests. The shift towards privatisation also means that private companies will need to be more vigilant in protecting their IP rights and ensuring compliance with regulatory standards. IP Protection and Enforcement IP protection is critical for fostering innovation and attracting investment in the pharmaceuti - cal sector. Saudi Arabia has made significant improvements in its IP protection and enforce - ment procedures. The SFDA and the SAIP have developed guide - lines to support pharmaceutical manufacturers in registering their products and protecting their IP. These guidelines include requirements for bioequivalence studies for generic drugs and clinical trials for vaccines. The SFDA’s guidelines on bioequivalence stud - ies for generic drugs and clinical trials for vac - cines are critical for ensuring drug safety and efficacy. These guidelines provide a clear frame - work for manufacturers to follow, reducing the
272 CHAMBERS.COM
Powered by FlippingBook